Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Envoy Medical ( (COCH) ) has issued an update.
On February 24, 2026, Envoy Medical announced it had regained compliance with Nasdaq’s continued listing standards, confirming it now meets the market value requirements under Listing Rule 5550(b). The move follows a February 25, 2025 notice from Nasdaq that the company had fallen below the $35 million minimum market value of listed securities threshold.
Management said the return to compliance was achieved after implementing strategic financing initiatives that substantially strengthened the company’s balance sheet. Regaining compliance secures Envoy Medical’s continued trading on the Nasdaq Capital Market under the COCH ticker, stabilizing its market position and reducing delisting risk for shareholders.
The most recent analyst rating on (COCH) stock is a Hold with a $0.58 price target. To see the full list of analyst forecasts on Envoy Medical stock, see the COCH Stock Forecast page.
Spark’s Take on COCH Stock
According to Spark, TipRanks’ AI Analyst, COCH is a Neutral.
The score is primarily constrained by very weak financial performance (minimal/contracting revenue, large losses, negative equity, and sustained cash burn). Technicals also lean bearish with a negative MACD and price below key moving averages. Corporate events provide some support via listing extension and capital-flexibility steps, but are offset by the minimum bid deficiency risk, while valuation is difficult to support due to losses and no dividend.
To see Spark’s full report on COCH stock, click here.
More about Envoy Medical
Envoy Medical Inc. is a hearing health company focused on innovative technologies for patients across the hearing loss spectrum. The Nasdaq-listed firm has pioneered fully implanted hearing devices, including the Esteem active middle ear implant, approved in the U.S. since 2010, and the Acclaim cochlear implant, an investigational device targeting severe to profound sensorineural hearing loss.
The company’s devices are designed to leverage the ear’s natural anatomy, providing invisible, 24/7 hearing solutions without external components. Envoy Medical’s market focus centers on improving access, usability, and long-term compliance for adults whose hearing loss is not adequately addressed by conventional hearing aids, aiming to enhance quality of life and differentiate itself within the medical device segment of the hearing industry.
Average Trading Volume: 699,218
Technical Sentiment Signal: Sell
Current Market Cap: $57.11M
See more insights into COCH stock on TipRanks’ Stock Analysis page.